Saving the Day.

Slides:



Advertisements
Similar presentations
What's New in Basal Insulin for Diabetes
Advertisements

Upfront Combination Therapy vs Step-Up Approach for PAH:
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Exploring Early Combination Therapy in PAH
Monitoring and Modifying Treatment in PAH
NOACs for Cancer-Associated Thrombosis:
Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.
An Update on Oral Prostanoids: Advancing Care for PAH?
Advances in Management of Perioperative Hypotension: It Takes a Team
Cardiogenic Shock.
The Clinical Enigma of Cardiogenic Shock
Thrombosis, Cancer, and NOACs
Progression After Cancer Immunotherapy in Advanced NSCLC
Angiotensin as a Vasopressor in Vasodilatory Shock
Advances in Vasodilatory Shock:
Modern Strategies for Basal Insulin Use in T2D
Progressive Fibrosing Interstitial Lung Diseases – Addressing the Challenges Concept of Progressive Fibrosing ILDs With Examples.
Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.
All About PAH:.
Adverse Neurohormonal Activation in HF Has Formed the Basis for Evidence-Based Pharmacologic Therapy
Tailoring Hemophilia Prophylaxis Therapy
Decision-making in the eRA of Treating to Target
Updates in Pulmonary Arterial Hypertension
Improving Outcomes for Severe Sepsis and Septic Shock: Tools for Early Identification of At-Risk Patients and Treatment Protocol Implementation  Emanuel.
Treating Vasodilatory Shock in the ICU
Activity Goals. Activity Goals Case Presentation.
Are We Closer to Personalized Medicine in MS?
Case Collection in RA: Highlights of an Interactive Workshop
AF and PCI in Practice.
Forming Effective Individualized Treatment Plans for Patients With Low-Risk MDS.
Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?
TAVR and the Risk of Thrombosis
PCSK9 Inhibitors and Cardiovascular Outcomes
Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
A Better Solution For Cancer Patients With VTE?
Gene Therapy: Past, Present, and Future
Examining the Latest Evidence in PAH
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
Translating the Latest and Greatest Advances in PAH Into Clinical Practice.
Using Heart Rate as a Biomarker in Clinical Practice.
EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.
Physiology Myocardial Oxygen Supply and Demanda,b.
Navigating Treatment Options in PAH
Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.
When Is Intrathecal Drug Delivery Appropriate?
Cancer-Associated Thrombosis
Oral Prostacyclin Pathway Agents in PAH
Add-On Therapy to Insulin in T1DM Management
PeaceHealth Southwest Hospital/Carson Tahoe Medical Center
Incorporating Prostacyclins Into Practice
Challenges in LA SCCHN.
Elevated Admission Plasma Glucose Following ACS
Improving Adherence to Antiplatelet Therapy After an ACS Event
A Multidisciplinary Perspective on the Management of Hypoparathyroidism.
Patient Stories in PAH: Sequential Therapy in a FC II Patient
Assessing the Burden of Hyperkalemia
When Is Intrathecal Drug Delivery Appropriate?
Breaking Barriers in PAH: Role of Novel Early Treatment Strategies
Prostacyclin Pathway Agents in Action
Assessing the Burden of Hyperkalemia
Incorporating New PAH Treatments Into Clinical Practice
Chest Pain Choice Trial design: Patients presenting to the ED with low risk chest pain were randomized to either use of a tailored decision aid or routine.
PAH Pathways: What Do the Data Tell Us?”
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
What's New in PAH?.
PCSK9 Inhibitors and Real-World Evidence
Fresh perspectives ON BASAL Insulins in diabetes care
The Power of As-Treated Analyses
Presentation transcript:

Saving the Day

Patient Case

Patient Case (cont)

Patient Case (cont)

Patient Case (cont)

Surviving Sepsis Campaign 2016 Algorithm

Vasopressor Options for This Patient

The Great Debate: Hemodynamic Response to β-Blockers

Titrating NE

What If the Patient Is Still Not at MAP Goal What If the Patient Is Still Not at MAP Goal? Potential Adjunctive Therapies

RAAS System

Angiotensin II Trials

ATHOS-3 Clinical Endpoint Results

Individualized Care in Critical Care

Catecholamine-Sparing Agents

Current and Contemplated Uses of Ang II

SCCM 2019 Critical Care Congress

Ang II in Practice and Risk of Thrombosis

Fast vs Slow Pressor Response

Surviving Sepsis Campaign Hour-1 Bundle 2018 Update

Surviving Sepsis Recommendations

Surviving Sepsis Recommendations (cont)

Treatment Goals in Sepsis

Abbreviations

Abbreviations (cont)

Abbreviations (cont)